Attention Deficit Hyperactivity Disorder
About Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity. It is a well established medical diagnosis with extensive research, treatment guidelines, and pharmaceutical and behavioral intervention options that have evolved over decades.
Trend Decomposition
Trigger: Increased awareness and recognition of ADHD across demographics; emphasis on diagnosis in both children and adults; ongoing research validating treatments and outcomes.
Behavior change: More people seek diagnosis and treatment; greater acceptance of ADHD as a valid condition; shifting towards multimodal management including medication, therapy, and digital tools.
Enabler: Advances in pharmacology, evidence based behavioral therapies, and digital health tools enabling remote assessment, monitoring, and support.
Constraint removed: Barriers to access reduced through telehealth, broader insurance coverage, and stigma reduction leading to earlier intervention.
PESTLE Analysis
Political: Public health policy supporting mental health funding and access to ADHD services.
Economic: Growth in pharmaceutical markets and digital therapeutics related to ADHD; cost considerations influence treatment choices.
Social: Greater recognition of adult ADHD; inclusive workplaces adapting to neurodiversity and accommodation needs.
Technological: Digital therapeutics, telemedicine, and data driven monitoring improving management and adherence.
Legal: Regulations governing medical treatments, privacy, and use of digital health data.
Environmental: Less emphasis on environmental causes; focus on biopsychosocial management and supportive environments.
Jobs to be done framework
What problem does this trend help solve?
Provides diagnosis, treatment, and ongoing support for ADHD to improve functioning and quality of life.What workaround existed before?
Limited access to consistent care, reliance on delayed diagnoses, and fragmented treatment approaches.What outcome matters most?
Improved executive function, sustained attention, and reduced impairment in daily activities.Consumer Trend canvas
Basic Need: Better cognitive regulation and attention support for daily living.
Drivers of Change: Growing recognition of adult ADHD, evidence based treatments, digital health accessibility.
Emerging Consumer Needs: Convenient assessment, flexible dosing, remote monitoring, and personalized care plans.
New Consumer Expectations: Timely access, transparent efficacy data, and integrated care across providers.
Inspirations / Signals: FDA approvals of digital therapeutics and real world evidence supporting comprehensive ADHD management.
Innovations Emerging: Digital therapeutics, AI assisted screening, and remote patient monitoring for ADHD.
Companies to watch
- Takeda - Manufacturer of Vyvanse (lisdexamfetamine), a major ADHD medication.
- Johnson & Johnson (Janssen Pharmaceuticals) - Developed and marketed Concerta in collaboration with other partners; active in ADHD drug development.
- Eli Lilly and Company - Produces Strattera (atomoxetine) and engages in ADHD research and treatments.
- Akili Interactive - Develops and markets digital therapeutics for ADHD, including EndeavorRx.
- CogniFit - Offers cognitive training tools that address attention and executive function challenges associated with ADHD.
- EndeavorRx - FDA approved digital therapeutic designed for pediatric ADHD.